RET and cancer: Indeed, some small molecules agents analyzed in this study were mainly multikinase-inhibitors (e.g. vandetanib: EGFR VEGFR RET) or substances (e.g. thalidomide) which affected a lot of cellular processes and antiangiogenesis was only part of anti-cancer mechanisms [34–37].